Hengrui Pharmaceuticals
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 3
- AI Drug Discovery Enters Its Validation Era
IT时报 reports that AI drug discovery is shifting from the speed of generating candidate molecules toward laboratory validation, clinical value, data governance, and regulation. At a forum in Shanghai, deputy director Li Xiangyu of the Shanghai Center for Drug Evaluation described the field as entering a “clinical-first, value-first” stage, while industry executives described the dry-lab and wet-lab validation gap, data scarcity, and the need for human oversight.
虎嗅 AI · 🔥 0 - MetiS and Eli Lilly sign AI-driven LNP delivery deal worth up to $1.1B
MetiS Therapeutics (7666.HK) announced on October 19 a strategic collaboration with Eli Lilly to research and discover new lipid nanoparticle (LNP) delivery solutions, including tissue-specific delivery for multiple treatment modalities. MetiS will use its AiLNP platform, driven by the NanoForge system, to develop next-generation LNP technology aimed at improving targeting and in-vivo distribution, while Lilly contributes drug discovery, development and commercialization resources. Under the terms, MetiS receives an upfront payment of more than $10 million and is eligible for up to $1.1 billion in development, regulatory and commercial milestones, plus tiered single-digit percentage royalties on annual net sales of collaboration products. DoNews, 36Kr and TMTPost described the deal as a platform-level collaboration, and 36Kr and TMTPost called it China's first generative-AI LNP platform export deal and the largest AI-driven extrahepatic LNP delivery collaboration; these ranking claims were not independently verified.
DoNews · 🔥 0 - AI pharma's pivotal test: Rentosertib Phase III readout due 2029
The article reports that Anew Labs, an AI drug-discovery company spun out of ByteDance, raised a $290 million first round at a $1.5 billion valuation, and that Anthropic has reportedly built a wet lab in the San Francisco Bay Area where Claude drives robots to run real biological experiments. It divides the AI pharma chain into three groups — upstream AI technology firms such as Insilico Medicine, midstream CRO/CDMO wet-lab service providers such as GenScript and Twist Bioscience, and downstream pharma companies including Fosun Pharma and Hengrui Pharmaceuticals — and cites brokerage estimates that AI can cut drug-discovery timelines by 70%-90% and total R&D cost by roughly 50%. The decisive test is Insilico's lead asset Rentosertib, whose Phase IIa showed a 98.4 mL mean lung-capacity gain at 60 mg versus a 20.3 mL decline in controls; its China Phase III began in July 2026 with 320 planned participants and top-line data expected in 2029.
36氪 人工智能 · 🔥 0
Experience and discussion from the community
Share my Hengrui Pharmaceuticals experienceAsk about Hengrui Pharmaceuticals
Nobody has shared their experience with Hengrui Pharmaceuticals yet.